Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Central European Institute of Technology. Official publication website can be found on muni.cz.

Authors	MANČÍKOVÁ Veronika ŠMÍDA Michal
Year of publication	2021
Type	Article in Periodical
Magazine / Source	International Journal of Molecular Sciences
MU Faculty or unit	Central European Institute of Technology
Citation
Web	https://www.mdpi.com/1422-0067/22/11/5536
Doi	http://dx.doi.org/10.3390/ijms22115536
Keywords	chimeric antigen receptor; immunotherapy; chronic lymphocytic leukemia; CD19
Description	Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Related projects:	CEITEC 2020